Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by NewAmsterdam Pharma N.V.

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers APGE ENGN NAMS NAMSW
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Tickers NAMS NAMSW
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.